Navigation Links
Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy
Date:5/14/2008

New technology from Varian Medical Systems delivers faster image-guided intensity-modulated radiotherapy (IMRT) to target tumors while sparing more

healthy tissue

COPENHAGEN, Denmark and AMSTERDAM, Netherlands, May 14 /PRNewswire-FirstCall/ -- Doctors in Denmark and the Netherlands have successfully carried out Europe's first clinical treatments using advanced RapidArc(TM) technology from Varian Medical Systems (NYSE: VAR). Cancer patients at Copenhagen's Rigshospitalet and Amsterdam's VU University medical center became the first people in Europe to benefit from this advanced form of intensity-modulated radiotherapy (IMRT).

Dr. Svend Aage Engelholm, chief radiation oncologist of the Department of Radiation Oncology at Copenhagen University Hospital (Rigshospitalet), says, "Our first image guided RapidArc treatment went perfectly and the only unusual aspect was that the patient joined the clinical team in a celebratory glass of champagne after treatment. He was certainly aware that this was the first clinical treatment of its kind in Europe." Dr. Engelholm said the actual treatment took just 75 seconds to deliver.

The 60-year-old patient, who is half-way through his scheduled treatment cycle, had been receiving five-field image-guided intensity-modulated radiotherapy (IMRT) and doctors decided to convert his treatment plan to RapidArc, which was commissioned on one of the hospital's Clinac(R) iX linear accelerators earlier in the week. "We knew that we would really be able to reduce the rectal dose to this patient by using RapidArc and, as it turned out, we reduced it by 15 percent," adds Dr. Engelholm. He added that, as of this week, RapidArc would be the hospital's standard treatment for all prostate cancer patients and other suitable indications would follow.

Clinicians in Amsterdam also carried out their first RapidArc treatment on a 59-year-old head/neck cancer patient. Dr. Ben Slotman, Professor and Chairman, Department of Radiation Oncology, VU University medical center, said, "As our patient was undergoing re-irradiation, it was important to minimize doses to the brainstem and critical structures. We were able to achieve an optimal plan quickly with RapidArc. We perform many IMRT treatments and will replace all such treatments with RapidArc over time, especially as treatment planning and dose verification only took 24 minutes, which is considerably faster than with standard IMRT."

The treatment in Amsterdam took place on a Trilogy(R) linear accelerator with advanced imaging using the machine's On-Board Imager(R) accessory.

Jiri Bocanek, Varian's senior product manager for delivery systems, said, "We greatly appreciate the dedicated work of these two cancer centers to make these fast and accurate treatments a reality. After more than a year of evaluation, testing and quality assurance work, we are very happy to see a smooth clinical introduction of RapidArc." He also paid tribute to the other European members of the RapidArc Council -- CRLC Val d'Aurelle in Montpellier, France and University Hospital in Zurich, Switzerland -- who are also soon to start clinical treatments with RapidArc.

RapidArc delivers a complete volumetric intensity-modulated radiation therapy treatment in a single arc of the treatment machine around the patient and makes it possible to deliver advanced image-guided IMRT two to eight times faster than is possible with conventional IMRT, including helical tomotherapy. Treatment planning analyses show that RapidArc matches or exceeds the precision of conventional IMRT systems and spares more of the healthy tissue surrounding the tumor. Unrelated clinical studies on radiotherapy correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

"RapidArc extends the versatility of Varian's image-guided radiotherapy system, adding volumetric arc therapy to other advanced capabilities including fixed-beam IMRT and stereotactic treatments," said Dow Wilson, president of Varian's Oncology Systems business. "By outfitting their treatment machine with this new capability, clinicians around the world have ensured that they will be able to offer cancer patients the most appropriate form of treatment according to each patient's specific needs."

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,600 people who are located at manufacturing sites in North America and Europe and in its 60 sales and support offices around the world. For more information, visit http://www.varian.com/.


'/>"/>
SOURCE Varian Medical Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Expansion and Relocation to New, State-Of-The-Art Facilities Marks Milestone in Effort to Roll Out New Tool for Cancer Diagnosis
2. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
3. Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. Fujifilm and the National Breast Cancer Foundation Provide Free Mammograms as Part of Images of Health Campaign
6. European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics Lung Cancer Drug
7. When to Wait and When to Treat? New Program Will Search for Biomarkers in Men With Prostate Cancer to Help Find an Answer
8. HER1 and HER3 VeraTag(TM) Assays are Now Available for Use in Development and Clinical Evaluation of Cancer Therapeutics
9. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
10. National Cancer Registrars Association and IMPAC Medical Systems Announce Best Paper Award Recipients
11. Sale of Colon Cancer Diagnostic Tool to Czech Republic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... NEW YORK , February 4, 2016 ... (OTCQB: QBIO), a biotechnology acceleration company is pleased to provide ... --> --> Over the last 3 months ... note and securities purchase agreements exceeding $1,000,000. As a result, ... under our Mannin Research Inc. license agreement and expect that ...
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... the fostering and monetization of intellectual property, today provided ... Uniden in the Northern District of Texas ... forward.  Inter Partes Re-examination ("IPR") ... Patent Office.  The IPR was initiated on only certain ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... ... (AI) and leading supplier of Semantic Graph Database technology has been recognized As ... Products ” by Corporate America Magazine. , “At Corporate America, it’s our priority ...
(Date:2/4/2016)... ... February 04, 2016 , ... Many of the engineers at FireflySci, Inc. have ... sets them apart from other cuvette manufacturers is their supercharged customer service and their ... top of this steady flow of inside information, they have recently revamped their manufacturing ...
Breaking Biology Technology:
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/20/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce the attainment of ... the result of the company,s laser focus on (and ... , it,s comprehensive, easy-to-use and highly affordable cloud-based technology ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):